authors
- Harb, WA
- Sessa, C
- Hirte, Holger
- Kaye, SB
- Simantov, R
- Banerjee, SN
- Christinat, A
- Sternberg, DW
- Singh, M
- Light, R
- Poondru, S
A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors.
Conferences
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
status
publication date
- May 20, 2011
has subject area
- 1103 Clinical Sciences (FoR)
- 1112 Oncology and Carcinogenesis (FoR)
- Oncology & Carcinogenesis (Science Metrix)
published in
- Journal of Clinical Oncology Journal